New Treatments for Vulvovaginal Candidiasis by Faro, Sebastian
Infectious Diseases in Obstetrics and Gynecology 4:247-254 (1996)
(C) 1996 Wiley-Liss, Inc.
New Treatments for Vulvovaginal Candidiasis
Sebastian Faro
Department of Obstetcs and Gynecology, Rush Medical Center, Chicago, IL
KEY WORDS
Vulvovaginal candidiasis; Candida; fluconazole
ulvovaginal candidiasis (VVC) is probably the
most common form of vaginal infection, al-
though bacterial vaginosis is believed to be more
frequent. 1,z Even though Candida assumes a role as
a pathogen, it is an opportunistic organism causing
systemic infections usually in patients who are im-
munosuppressed or critically ill on multiple antibi-
otics. However, several studies have demonstrated
that C. albicans is a member of the host’s endog-
enous vaginal and gastrointestinal microflora. Au-
ger and Jolly3 isolated Candida from approximately
70% of healthy women. Other investigators4-6 have
isolated C. albicans from the lower genital tracts of
healthy, asymptomatic women with a frequency of
5-55%.
It is estimated that 75% of all women will ex-
perience one episode of symptomatic VVC during
their lifetime.7,8 Unfortunately, 40-50% of women
will have at least one recurrence of VVC and at
least 5% will have chronic or repeated episodes of
VVC.
Perhaps this condition should be viewed as a
disturbance in the vaginal ecosystem rather than a
disease in view of the fact that Candida is part of
the complex endogenous microflora of many indi-
viduals. Alterations in the vaginal ecosystem can be
favorable to the growth of C. albicans and other
species. Once the yeast becomes dominant, it may
result in a symptomatic condition and even pro-
duce findings consistent with acute infection. No
doubt, the symptomatic condition is extremely
prevalent, as evidenced by the 13 million prescrip-
tions written in the United States between 1980
and 1990.1
While C. albicans is the predominant yeast, caus-
ing 85-90% of all cases of VVC, information is
slowly being accumulated on a rising incidence of
VVC due to non-albicans species such as C. (Toru-
lopsis) glabrata, C. tropicalis, and C. krusei (Table 1).9
This rising incidence has become even more of a
concern in view of the availability of several anti-
mycotic agents that no longer require a prescription
(over-the-counter products). The easy accessibility
of antimycotic intravaginal preparations has raised
at least three major concerns: 1) The wanton or
indiscriminate use of these agents may exert selec-
tive pressure for resistant strains; 2) the indiscrimi-
nate use of these agents may allow for replacement
by other species such as C. glabrata, C. tropicalis, or
C. krusei; and 3) the treatment may be misdirected
if the individual has another or concomitant infec-
tion. Added to these concerns is the fact that the
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TABLE I. Species of Candida known to cause VVC
Species Incidence (%)
C. albicans 90
C. glabrata 5
C. guilliermondi <1
C. krusei <1
C. lusitaniae <
C. parapsilosis <1
C. pseudotropicalis <1
C. rugosa <1
C. tropicalis <1
imidazoles are less effective against non-albicans
species.lO. 11
This trend of non-albicans species to occur more
frequently is significant in other ways. Horowitz et
al. lz,3 and MacGregor4 reported that patients
with C. tropicalis VVC were twice as likely to ex-
perience a recurrence than individuals infected
with C. albicans. The incidence of non-albicans spe-
cies has focused on C. tropicalis and C. glabrata;
however, a recent increase in the isolation of C.
lusitaniae and C. parapsilosis has been noted. In fact,
the incidence of non-albicans species involved in
VVC was 9.9% in the 1970s and rose to 21.3% in
the 1980s.5,16 Moreover, the role of C. glabrata in
recurrent VVC appears to be gaining significance,
causing 22.7-30.5% of the cases.6-18 However,
there seems to be a controversy over the incidence
of C. glabrata as a causative agent for vulvovaginitis.
Several investigators continue to report that C. al-
bicans is responsible for 85-90% of the cases of
VVC. 18a-c To solve this growing dilemma, we
should seek to answer two questions: 1) Is there a
true change in colonization of the human host,
namely the gastrointestinal tract which appears to
be the reservoir, and the lower genital tract? 2) Is
this change in Candida species bringing with it a
resistance to the traditionally employed intravagi-
nal agents?
PATHOPHYSIOLOGY OF VVC
Candida is not believed to initiate an infection of
the vulva and vagina based simply on its presence.
On the contrary, the organism can easily be cul-
tured from the lower genital tracts of 20-40% of
women who have no symptoms of vaginitis.5,x4
Therefore, it is unlikely that Candida is introduced
into the lower genital tract prior to the onset of
symptoms. More likely, a change in the vulvovagi-
nal ecology favors the growth of Candida.
Candida is a dimorphic fungus capable of grow-
ing as a typical yeast by budding or as a filamentous
form by producing pseudohypha. Typically, the or-
ganism grows by forming buds attached to the
mother cell or by forming blastospores or blastoco-
nidia. The presence of germ tubes and pseudohy-
pha, which tends to be associated with symptom-
atic VVC, allows the organism to adhere to the
vaginal epithelium. This ability to adhere to the
vaginal epithelium fulfills one requirement of the
establishment of an infection. Another require-
ment is fulfilled when the pseudohypha invades
the squamous epithelium lining the vagina. Can-
dida produces a substance known as Candida in-
hibitory product (CHIP) which blocks the release
of lysosomes from polymorphonuclear leukocytes,
thereby interfering with the host’s ability to de-
stroy yeast cells. 4,19 Although the yeast form of C.
albicans is able to adhere to epithelial cells, the
presence of a germ tube appears to confer a greater
ability to adherence,z
TREATMENT OF VVC
The treatment of VVC has focused on the use of
intravaginal cream or suppositories. Until recently
oral agents have been reserved for recalcitrant or
persistent infections. Currently, oral fluconazole,
150 mg, is available for the treatment of acute VVC.
Intravaginal preparations have been favored be-
cause of their limited systemic absorption, rapid
relief of symptoms, and minimal potential for side
effects. The rapid relief of symptoms is thought to
be a significant secondary gain of intravaginal an-
timycotics, especially the cream preparations. It is
interesting to note that the evolution of intravagi-
nal antimycotic agents has involved the develop-
ment of shorter and shorter regimens. The treat-
ments are administered for 3 days such as tercona-
zole (Terazol (R), Ortho Pharmaceutical Corporation,
Raritan, NJ), or for day, such as tioconazole (Vagi-
stat(R), Fujisawa SmithKline Corporation, Bala Cyn-
wyd, PA) (Table 2). An algorithm for the manage-
ment of acute VVC is given in Figure 1.
Prior to the introduction of fluconazole, 150 mg,
oral antimycotic therapy used for the treatment of
VVC has not enjoyed much popularity. Ketocona-
zole (Nizoral (R), Janssen Pharmaceutica, Inc., Piscat-
away, NJ) has not been used widely except in the
immunosuppressed patient or the individual with
chronic, recurrent, or persistent infection because
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TABLE 2. Antifungal agents for treatment ofWC
Agent Regimen Route
Nystatin (polyene) 14 days b.i.d. Intravaginal
Butoconazole (imidazole) 3--6 days q.d. Intravaginal
Clotrimazole (imidazole) 3-7 days q.d. Intravaginal
Miconazole (imidazole) 3-7 days q.d. Intravaginal
Tioconazole (imidazole) day Intravaginal
Terconazole (triazole) 3-7 days Intravaginal
Fluconazole (triazole) day Oral
Ketoconazole (triazole) 14 days Oral
Itraconazole (triazole) day b.i.d. Oral
VULVOVAGINAL ITCHING
AND/OR BURNING |
DOCUMENT CANDIDA 1 BY MICROSCOPIC EXAMINATION |
OF VAGINAL DISCHARGE I
I TREAT wITH ONEF THE)LLoWING:
| DIFLUCAN, 150 MG, SINGLE ORAL DOSE;
| VAGISTAT-1,300MG, SINGLE INTRAVAGINAL DOSE;
I
TERAZOL -3, 80 .G, 3-DAY ,NTRAVAGINALDOSE
Fig. I. Algorithm: management of acute WC.
of its adverse effects. The most common adverse
effects are nausea, vomiting, abdominal pain, inhi-
bition of androgen biosynthesis, and hepatotoxici-
ty.zl Hepatotoxicity has caused a significant con-
cern, after having been originally reported to occur
in 1/10,000 ketoconazole-treated patients and later
in 1/70,000. However, ketoconazole is usually pre-
scribed for a shorter duration in patients with VVC,
thus having less chance of adverse effects. Hepa-
totoxicity occurs more frequently in women than in
men. It also occurs more frequently in patients
treated for chromomycosis, previously treated with
griseofulvin, or treated with ketoconazole for more
than 2 weeks, as well as in patients older than 50
years,zz
Fluconazole (Diflucan(R)), a new triazole, is an
orally administered antifungal agent that is effec-
tive against C. albicans as well as C. parapsilosis, C.
glabrata, and C. tropicalis. In vitro sensitivity studies
of 384 isolates of C. albicans revealed 8.8% to be
resistant to fluconazole; of 84 isolates of C. tropica-
lis, 34.5% were resistant; of 84 isolates of C. gla-
brata, 19.1% were resistant; and of 69 isolates of C.
parapsilosis, 4.4% were resistant to fluconazole,z3
The imidazoles tend to be ineffective in the treat-
ment of non-albicans VVC.1
Fluconazole offers an advantage in that a single
150-mg tablet is as effective as 3- or 7-day admin-
istration of intravaginal clotrimazole,z4 Further-
more, a single 150-mg oral dose of fluconazole is
not only as effective as 3 days of intravaginal clo-
trimazole, but also is as effective as 5 days of oral
ketoconazole or a single dose of miconazole or ec-
onazole,z5-z8 There appears to be no difference
with regard to recurrent disease between oral flu-
conazole and any of the intravaginal topical treat-
ments.
The effectiveness of a single dose of fluconazole
is most likely due to its ability to achieve signifi-
cant concentrations and remain in the tissues for a
prolonged time. Fluconazole concentrations in the
vaginal tissues following a single 150-mg orally ad-
ministered tablet were found to be 3.18 pg/g at 6 h
and 0.54 pg/g at 72 h.z9 In plasma, the concentra-
tions were 2.82 pg/nl at 6 h and 2.42 pg/nl at 72 h.
Fluconazole can be detected in vaginal secretions
for at least 7 days, but the concentration is slightly
higher than the concentration in the vaginal tissues.
In addition to persistent tissue concentrations, which
may play a significant role in preventing recurrences,
orally administered fluconazole combats Candida in
the gastrointestinal tract, which is considered by
some investigators to be the reservoir,z6
Comparative studies between fluconazole and
intravaginal antimycotics administered in a single
course or multiple courses revealed all agents to be
equivalent with regard to mycological cures.3
Symptomatic relief was achieved in day with flu-
conazole and in 2 days with intravaginal clotrima-
zole. Complete reliefwas achieved within 2-3 days
with fluconazole and intravaginal clotrimazole, re-
spectively.31
Fluconazole is similar to ketoconazole in regard
to adverse effects. The most common adverse ef-
fects reported following an oral dose of fluconazole
were nausea (2.1%), headache (0.9%), abdominal
pain (0.7%), diarrhea (0.6%), and dyspepsia
(0.6%).30 These side effects have also been re-
ported with ketoconazole and itraconazole. In a
study of intravaginal antimycotics, 4% of the pa-
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tients experienced adverse effects, namely, vaginal
burning, itching, pain, and discharge.3
Liver abnormalities occurred in both the group
receiving fluconazole (3.3%) and in the group re-
ceiving either an oral or intravaginal antimycotic
(2.9%), with no significant difference between the
two. These transient laboratory abnormalities were
noted to be normal at the long-term follow-up ex-
aminations,zl,3,31
A single 150-mg oral dose of fluconazole taken
after the last menstrual period was not found to be
associated with fetal abnormalities or an increased
risk of spontaneous abortion. Pregnant women who
had taken a single 150-mg dose of fluconazole after
their last menses were found to have an overall rate
of fetal abnormalities of 2.5%, which was not dif-
ferent from the 2% rate in the general popula-
tion.3Z,33
Additional side effects have been reported with
fluconazole but not at a significant rate. The most
common of these are dizziness, dry mouth, rash,
and dry skin.8,34,3s
DRUG INTERACTIONS
Drug interactions with intravaginal preparations are
rare because of the limited absorption of these
agents into the patient’s bloodstream. Concern
over the oral agents has been greater because of the
systemic absorption of these agents from the gas-
trointestinal tract. Both ketoconazole and flucona-
zole are equipotent inhibitors of fungal cytochrome
P-450 enzymes; however, fluconazole has 100
times the inhibitory activity for fungal enzymes
than ketoconazole has.36,37
There have not been any reports of drug inter-
actions between fluconazole and antipyrine or oral
contraceptives. Fluconazole did not affect the level
of estradiol nor the pharmacokinetics of ethinyl es-
38 39 tradiol or norgestrel..
The drugs that have been reported to interact
with fluconazole are listed in Table 3. These in-
teractions occurred in patients who were receiving
high doses of fluconazole. To date, no clinically
significant drug interactions have been reported
following a single 150-mg dose of fluconazole.4z-s
RESISTANCE TO ANTIFuNGALAGENTS
A variety of regimens has been used in the treat-
ment of chronic VVC, ranging from a daily to a
weekly or monthly administration,s3 The readily
TABLE 3. Drugs that interact with fluconazole
Phenytoin
Warfarin
Cyclosporine
Rifampin
Zidovudine
aCyclosporine doses of >200 mg may Increase serum levels of flucona-
zole.
bLowers levels of fluconazole by up to 30%.
available antifungal agents, i.e., over-the-counter
intravaginal azoles, have focused a great deal of
attention on the potential of Candida to develop
resistance to these agents. Also adding to this con-
cern has been the use of these agents in a prophy-
lactic or suppressive role in patients with chronic
VVC.
It is estimated that over 20 million prescriptions,
including over-the-counter usage, are written an-
nually for intravaginal medications for the treat-
ment of VVC. However, the use of intravaginal
agents for VVC exceeds that number in view of
over-the-counter agents. In spite of this over-
whelming usage of antimycotics, both intravaginal
and oral preparations, the development of resis-
tance by C. albicans appears to be a rare event.
Seven cases of C. albicans azole resistance have
been reported, all in patients receiving high dose
therapy.54 Three of the isolates were resistant to
miconazole and four to ketoconazole. There have
been no reports of resistance developing with
single, 7-, or 14-day therapy with intravaginal
preparations. Similarly, no resistance has been
noted to emerge as the result of oral single-day
treatments.
CHRONIC VVC
There is little doubt that VVC is a common condi-
tion. It inflicts a great deal of suffering on the in-
dividual, especially one who has chronic or recur-
rent VVC. The approach to treating chronic or re-
current VVC has been to use intravaginal or oral
antimycotics in an attempt to cure the acute epi-
sode, followed by a program of maintenance
therapy over a prolonged time, e.g., 4-6 months.
Maintenance therapy is defined as the administra-
tion of an antimycotic once a month. The purpose
of the monthly administration is to suppress the
growth of Candida. However, the use ofan agent on
a monthly basis seems to be doomed to failure in
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view of the fact that Candida is part of the endog-
enous microflora of the vaginal ecosystem. Since
Candida can be isolated from approximately 40% of
asymptomatic women whose vaginal ecosystem
may be in a balanced state, achieving therapeutic
success might be better directed to reestablishing a
healthy or balanced vaginal ecosystem.
It is often not possible to identify the factor(s)
responsible for upsetting the delicate equilibrium
of a balanced vaginal ecosystem. Nevertheless, it
seems logical to try to suppress the growth of Can-
dida long enough to allow the microbes that are
antagonistic to the growth of the yeast to flourish.
Such suppression might be accomplished with a
short course of therapy, either oral or intravaginal,
e.g., single-dose therapy with either fluconazole,
150-mg oral tablet, or intravaginal cream, tiocona-
zole, 300-mg ointment. Short-course therapy may
also be accomplished with a 3-day regimen of ter-
conazole, 80 mg (see Fig. 1). Since these short-
course regimens are as effective as the traditional
longer therapeutic regimens, the former would
probably achieve a better level of compliance. An
algorithm for the management of chronic VVC is
presented in Figure 2.
CONCLUSIONS
VVC is a common condition inflicting a great deal
of suffering on the infected patient, especially if
she has chronic or recurrent infections. The ap-
proach to treating this condition has been to use
intravaginal or oral antimycotics in an attempt to
effect a cure. However, the objective of effecting a
cure may be inappropriate. Since Candida is part of
the endogenous microflora of the vaginal ecosys-
tem, a more logical approach would be to reestab-
lish a healthy or balanced vaginal ecosystem.
A healthy vaginal ecosystem could be achieved
with either oral or vaginal short-course therapy.
Single-dose therapy could be accomplished with
oral fluconazole, 150 mg, or intravaginal tiocona-
zole, 200 mg, or a 3-day regimen of terconazole
(Fig. 1). These agents are as effective as longer
therapeutic regimens, so the shorter therapeutic
regimen should be associated with better compli-
ance.
The concept of treating VVC as a disturbance of
the vaginal ecosystem and not a disease is sup-
ported by the high relapse rate common to all
therapeutic regimens. VVC does not result from
PATIENT HAS RECURRENT
OR PERSISTENT SYMPTOMS
OF VULVOVAGINAL CANDIDIASIS
DOCUMENT CANDIDA BY MICROSCOPIC
EXAMINATION OF VAGINAL DISCHARGE
CANDIDAGLABRAT I cA’’ID’A AI’’BICANS
SPECIES OTHER _L_..
THAN C. ALBICANS
BORIC ACID, 600 MG I FOLOWING: I
INTRAVAGINAL | DIFLUCAN,100 MG, |
CAPSULES, BID X 7 DAYS/ ORALLY, BID ON DAY |
THEN 100 MG, QD X 5 |
RESOLUTION RESOLUTION
BEGIN MAINTENANCE THERAPY
DIFLUCAN,150 MG, ORALLYQWEEK X 6 WEEKS
OR
VAGISTAT-1,300 MG, INTRAVAGINALLY
QWEEK X $ WEEKS
Fig. 2. Algorithm: management of chronic WC.
the introduction of the fungus into the vagina, but
from the factor(s) that stimulates the growth of
Candida. This growth occurs when the antagonistic
effect of other microflora is overcome and, most
likely, a physiologic alteration is produced that fa-
vors the growth of Candida while inhibiting the
growth of its antagonistic microbes. Therefore,
treatment directed at killing Candida without
knowing what environmental factor(s) regulates
the growth of this fungus can only result in recur-
rent episodes of VVC. Patients with chronic or re-
currentVVC should be approached with the goal of
suppressing the growth of yeast, thereby reducing
the yeast population below a critical threshold to
render their presence asymptomatic. This ap-
proach, by altering the environment, would result
in a correction of the environmental disturbance
and resolution of the chronic condition.
Prior to undertaking suppressive therapy, it is
extremely important that the patient’s current epi-
sode ofVVC be resolved. The principle of suppres-
sive, maintenance, or prophylactic therapy is to
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TABLE 4. Factors that may contribute to VVC
Diabetes mellitus
Acquired immunodeficiency syndrome
Exogenous estrogen therapy
Use of oral contraceptives
Use of antibiotics
prevent the growth or resurgence of Candida, not to
eradicate the organism, cure the patient, or cure a
symptomatic infection. Additionally, intrinsic or
extrinsic contributing factors should be sought.
Table 4 cites the factors believed to predispose a
patient to VVC, although they have not been sub-
stantiated as such.53,55
Other possible contributing factors are rectal or
gastrointestinal colonization and penile coloniza-
tion of male sexual partners ofwomen with chronic
VVC. Although data exist both to support and not
to support the role of gastrointestinal colonization
as a contributing factor to the perpetuation ofVVC,
it is still an issue in patients with chronic VVC.
While studies using oral nystatin did not result in a
resolution of chronic VVC,56,57 other studies of re-
current or chronic VVC have demonstrated that the
Candida strain isolated from the patient’s vagina
and the strain from the rectum are identical in the
majority of cases.56,58 Therefore, until this issue is
settled, the physician should not discount the pos-
sibility of gastrointestinal carriage as a contributing
factor to the recurrence of VVC.
The possibility that VVC is a sexually transmit-
ted disease has been neither substantiated nor dis-
proved. Candida has been isolated from the penile
skin of 20% of the male partners of women with
chronic VVC.59,60 Although asymptomatic coloni-
zation of the males occurs, it is 4 times more likely
to occur in the male partners ofwomen with recur-
rent VVC infections.6 Additional support of the
role of sexual transmission cannot be ruled out. For
this reason, treating the male partner should be
considered in the therapy of the woman with
chronic VVC. If treatment of the male is contem-
plated, a systemic agent, such as fluconazole,
should be utilized to target not only the coloniza-
tion of the penile skin but also the prostate gland
and gastrointestinal tract.
Evidence suggests that women with chronic or
recurrent VVC had a defect in cell-mediated im-
munity.63-64 A specific impairment of the T-
lymphocyte is a response to Candida antigen, while
a normal proliferative response occurs to mitogens
and other non-Candida antigens in women with re-
current or chronic VVC.65
Prior to the approval of fluconazole, the prophy-
lactic or maintenance administration of oral keto-
conazole or intravaginal antimycotics reduced the
frequency of recurrent episodes ofVVC. The need
for an oral agent became apparent because of the
prolonged administration required with antimy-
cotics. However, the available agents required daily
administration. Ketoconazole was administered at
an initial dose of 400 mg daily for 5 days beginning
on the first day of menstruation each month for 6
months. The most effective regimen was the 100-
mg daily dose for 6 months, with only 5% of the
patients experiencing a recurrence.37 Nevertheless,
upon cessation of the prophylaxis, approximately
50% of the patients relapsed.
In a multicenter, international, double-blind,
placebo-controlled clinical trial, the patients were
given either fluconazole, 150 mg, or placebo once a
month for 12 months.66 Sixty-eight percent of the
patients receiving the placebo experienced recur-
rences ofVVC, whereas 42% of the patients receiv-
ing fluconazole had recurrences (P--- 0.02). Patients
in the placebo group experienced a 3-fold increase
per patient of recurrent infection. No serious side
effects were noted to have occurred.
In the European study of this international trial,
the patients received 150 mg of fluconazole or pla-
cebo once a month for 4 months.66 All patients
were examined 6 months after the cessation of flu-
conazole prophylaxis. In this patient population,
53% of those receiving placebo experienced recur-
rent VVC compared with 39% of those receiving
fluconazole (P-- 0.05). Over the 6-month follow-up
period, no difference was noted with regard to re-
currence of VVC between the two groups.
Fluconazole offers two benefits over ketocona-
zole when used for therapy or prophylactic main-
tenance. First, fluconazole therapy is associated
with less toxicity. Second, because of its long half-
life, fluconazole can be given as a single dose for
therapy and once a month for suppression. How-
ever, it may be more beneficial to administer pro-
phylaxis once a week for 6-12 weeks to expose the
areas colonized by C. albicans to a constant, not
intermittent, concentration of fluconazole.
An alternative to fluconazole would be the
3-times-weekly administration of Vagistat-1 or
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Terazol, leaving the choice up to the patient. Since
there are no data addressing this issue, I would
recommend a weekly application for 6 weeks.
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